Newsroom

Celdara Medical, LLC announced today that it has received a $3.2M SBIR Phase II award from the National Institutes of Health’s National Heart, Lung, and Blood Institute (NHLBI). This award will support the preclinical and clinical development of Celdara Medical’s chimeric antigen receptor (CAR) T cell therapy. “Other CAR therapies […]

Celdara Medical, LLC announced today that it has received a $2.1M SBIR Phase II award from the National Institutes of Health’s National Heart, Lung, and Blood Institute (NHLBI). This award will support the preclinical development of Celdara Medical’s dendritic cell targeted therapy for myocardial infarction-induced ischemia-reperfusion injury. “Myocardial infarction is […]